116 related articles for article (PubMed ID: 17674980)
1. Radiotherapy adapted to spatial and temporal variability in tumor hypoxia.
Søvik A; Malinen E; Skogmo HK; Bentzen SM; Bruland OS; Olsen DR
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1496-504. PubMed ID: 17674980
[TBL] [Abstract][Full Text] [Related]
2. Predicting the effect of temporal variations in PO2 on tumor radiosensitivity.
Kirkpatrick JP; Cárdenas-Navia LI; Dewhirst MW
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):822-33. PubMed ID: 15183486
[TBL] [Abstract][Full Text] [Related]
3. Adapting radiotherapy to hypoxic tumours.
Malinen E; Søvik A; Hristov D; Bruland ØS; Olsen DR
Phys Med Biol; 2006 Oct; 51(19):4903-21. PubMed ID: 16985278
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma: to treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord.
Chau RM; Teo PM; Kam MK; Leung SF; Cheung KY; Chan AT
Med Dosim; 2007; 32(4):263-70. PubMed ID: 17980826
[TBL] [Abstract][Full Text] [Related]
5. Dynamic contrast enhanced magnetic resonance imaging of bladder cancer and implications for biological image-adapted radiotherapy.
Røe K; Muren LP; Rørvik J; Olsen DR; Dahl O; Bakke A; Malinen E
Acta Oncol; 2008; 47(7):1257-64. PubMed ID: 18618299
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric comparison between 3DCRT and IMRT using different multileaf collimators in the treatment of brain tumors.
Ding M; Newman F; Chen C; Stuhr K; Gaspar LE
Med Dosim; 2009; 34(1):1-8. PubMed ID: 19181248
[TBL] [Abstract][Full Text] [Related]
7. The impact of different dose-response parameters on biologically optimized IMRT in breast cancer.
Ferreira BC; Mavroidis P; Adamus-Górka M; Svensson R; Lind BK
Phys Med Biol; 2008 May; 53(10):2733-52. PubMed ID: 18448874
[TBL] [Abstract][Full Text] [Related]
8. A split-organ delineation approach for dose optimisation for intensity-modulated radiotherapy for advanced T-stage nasopharyngeal carcinoma.
Chau RM; Leung SF; Kam MK; Cheung KY; Kwan WH; Yu KH; Chiu SK; Chan AT
Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):134-41. PubMed ID: 18031999
[TBL] [Abstract][Full Text] [Related]
9. Normal tissue complication probability: does simultaneous integrated boost intensity-modulated radiotherapy score over other techniques in treatment of prostate adenocarcinoma.
Basu KS; Bahl A; Subramani V; Sharma DN; Rath GK; Julka PK
J Cancer Res Ther; 2009; 5(2):78-84. PubMed ID: 19542662
[TBL] [Abstract][Full Text] [Related]
10. DCEMRI monitoring of canine tumors during fractionated radiotherapy.
Søvik A; Kippenes Skogmo H; Bruland ØS; Rune Olsen D; Malinen E
Acta Oncol; 2008; 47(7):1249-56. PubMed ID: 18618342
[TBL] [Abstract][Full Text] [Related]
11. Comparison between the ideal reference dose level and the actual reference dose level from clinical 3D radiotherapy treatment plans.
Bufacchi A; Arcangeli G; delle Canne S; Malatesta T; Capparella R; Fragomeni R; Marmiroli L; Begnozzi L
Radiother Oncol; 2009 Jul; 92(1):68-75. PubMed ID: 19328571
[TBL] [Abstract][Full Text] [Related]
12. DCEMRI of spontaneous canine tumors during fractionated radiotherapy: a pharmacokinetic analysis.
Søvik S; Skogmo HK; Andersen EK; Bruland ØS; Olsen DR; Malinen E
Radiother Oncol; 2009 Dec; 93(3):618-24. PubMed ID: 19747746
[TBL] [Abstract][Full Text] [Related]
13. Feasibility study of intensity-modulated radiotherapy (IMRT) treatment planning using brain functional MRI.
Chang J; Kowalski A; Hou B; Narayana A
Med Dosim; 2008; 33(1):42-7. PubMed ID: 18262122
[TBL] [Abstract][Full Text] [Related]
14. Large cohort dose-volume response analysis of parotid gland function after radiotherapy: intensity-modulated versus conventional radiotherapy.
Dijkema T; Terhaard CH; Roesink JM; Braam PM; van Gils CH; Moerland MA; Raaijmakers CP
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1101-9. PubMed ID: 18472355
[TBL] [Abstract][Full Text] [Related]
15. Adapting biological feedback in radiotherapy.
Søvik A; Malinen E; Olsen DR
Semin Radiat Oncol; 2010 Apr; 20(2):138-46. PubMed ID: 20219552
[TBL] [Abstract][Full Text] [Related]
16. Tumor control probability (TCP) and normal tissue complication probability (NTCP) in head and neck cancer.
Grégoire V
Rays; 2005; 30(2):105-8. PubMed ID: 16294902
[TBL] [Abstract][Full Text] [Related]
17. TCP and NTCP in preclinical and clinical research in Europe.
Baumann M; Petersen C; Krause M
Rays; 2005; 30(2):121-6. PubMed ID: 16294904
[TBL] [Abstract][Full Text] [Related]
18. Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study.
Søvik A; Malinen E; Bruland ØS; Bentzen SM; Olsen DR
Phys Med Biol; 2007 Jan; 52(2):499-513. PubMed ID: 17202629
[TBL] [Abstract][Full Text] [Related]
19. Comparison of traditional and simultaneous IMRT boost technique basing on therapeutic gain calculation.
Slosarek K; Zajusz A; Szlag M
Med Dosim; 2008; 33(4):299-302. PubMed ID: 18973858
[TBL] [Abstract][Full Text] [Related]
20. Clinical heterogeneity and tumor control probability.
Eisbruch A
Acta Oncol; 2010 Nov; 49(8):1385-7. PubMed ID: 20500028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
